Author Archive: Tracy Cooley

Tracy Cooley

Tracy serves as the Director of Events Communications and handles all communications for BIO’s events and emerging company policy issues. She loves blogging and podcasting on all things biotech and believes in the great potential of the industry, looking for every opportunity to spread the message far and wide. Nearly everyone in her family is a golfer, and as such, she has what many people have called a “natural” swing. Sometimes she even hits the ball. Tracy just finished her ninth marathon, and has nearly mastered the skill of one-foot-in-front-of-the-other (usually, sometimes the laces get in the way). The joy of her life is her five-year-old daughter Josephine.

Latest Posts

Richard Pops: A Greater Patient Voice in Drug Development

ph-summit

In the October issue of MedNous, Alkermes’ CEO Richard Pops writes about the move toward increased engagement with patients in the development, review and delivery of new medicines, as well as the challenges and opportunities associated with access and reimbursement. Pops asserts that patients must organize to share data that can be used in regulatory decision-making. Furthermore, he writes that this input must be integrated through the process – from the early stages of development Read More >

Events, Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Forbes profiles a medical miracle and the value of cures

kids

This week, Forbes’ Matthew Herper wrote a moving story about a girl who is a medical miracle at only 5-years-old. When Evie Elsaesser was born, she was only expected to live a few hours as her bones were soft and un-calcified. Shortly afterwards, Evie was enrolled in a clinical trial for a drug that replaced the bone-forming enzyme that she was missing. While she suffered from side effects and endured a long road to being Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , ,

Ebola Highlights Importance of Vaccine Development in Protecting Global Health

21st-Century-Cures--Free

The current Ebola crisis shows how government regulators and research institutions, global health organizations, and biopharmaceutical research companies can work collaboratively and efficiently to speed the development of novel vaccines and therapeutics in response to an urgent global health problem. Yet just as importantly, it underscores the need to move innovation forward before a crisis breaks out in order to prevent illness and suffering, and save the lives of countless people around the world. Vaccines Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Center for Medicine in the Public Interest Challenges Accuracy of 60 Minutes Cancer Story

scientist-eyedropper

This week, the Center for Medicine in the Public Interest issued a press release criticizing CBS’ “60 Minutes” segment on cancer treatment prices as not just distorted but ‘dead wrong.’ “Featuring physicians that argue that treatment prices are too high does not change the fact that the cost of cancer drugs are about 12 percent of what health insurers spend on cancer or that new cancer drugs actually save health insurers money. Yet insurers are Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Tony Coelho: A Patient Advocate’s Perspective on Paying for Value

lab_tech

Yesterday, Health Affairs published an op-ed by Tony Coelho, Former Member of the U.S. House of Representatives and Chairman of the Partnership to improve patient care, on the benefit of patient-centered outcomes research to better inform medical care, without limiting patients’ and providers’ choices. As Coelho writes, ‘The movement to place greater financial risk on providers in an effort to pay for value rather than volume will have the effect of fundamentally changing the way Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,